Status:
COMPLETED
Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia
Lead Sponsor:
Asan Medical Center
Conditions:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Eligibility:
All Genders
18+ years
Brief Summary
This is a multicenter, retrospective, observational study to validate a pharmacogenetics model for imatinib metabolism and resistance in patients with chronic myeloid leukemia among patients in differ...
Detailed Description
1. The activity of Imatinib(IM) is mediated by blocking the activity of BCR/ABL tyrosine kinase in CML cells. However, some of the patients failed to achieve optimal response, and a substantial propor...
Eligibility Criteria
Inclusion
- Chronic myeloid leukemia of any stage including chronic phase, accelerated or blastic phase.
- Age\>18 years
- Complete set of clinical data available for review (demographic data, stage, treatment history, cytogenetic reports, and latest BCR/ABL RQ-PCR results)
- Treated with imatinib mesylate at least 3 months
Exclusion
- Treated with imatinib mesylate less than 3 months
- Not agree with the intention of this study
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01437202
Start Date
September 1 2011
End Date
October 1 2012
Last Update
July 9 2014
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Hospital, University of Toronto
Toronto, Canada
2
Asan Medical Center, University of Ulsan College of Medicine
Seoul, South Korea
3
Samsung Medical Center, Sungkyunkwan University School of Medicine
Seoul, South Korea